Gomez-Peralta Fernando, Escalada San Martín Francisco Javier, Menéndez Torre Edelmiro, Mata Cases Manel, Ferrer García Juan Carlos, Ezkurra Loiola Patxi, Ávila Lachica Luis, Fornos Pérez Jose Antonio, Artola Menéndez Sara, Álvarez-Guisasola Fernando, Rica Echevarría Itxaso, Girbés Borrás Juan
Unidad de Endocrinología y Nutrición, Hospital General de Segovia, Segovia, España.
Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Pamplona, España; Diabetes y Enfermedades Metabólicas, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, España; Departamento de Endocrinología y Nutrición, Clínica Universidad de Navarra, Pamplona, España.
Endocrinol Diabetes Nutr (Engl Ed). 2018 Dec;65(10):611-624. doi: 10.1016/j.endinu.2018.08.004. Epub 2018 Oct 23.
Type 2 diabetes mellitus (DM2) has become a problem of global dimensions by their high and growing prevalence worldwide and the personal and economic costs associated with it. Correct treatment can reduce mortality and associated complications. New concepts have recently been included in routine clinical practice and have changed the algorithm of DM2 pharmacological therapy. Therefore, the Spanish Society of Diabetes (SED) entrusted to the Working Group of Consensus and Clinical Guidelines an update of the 2010 document Recommendations for Pharmacological Treatment of Hyperglycemia in Diabetes type2. Novel aspects include nine characteristics to describe each drug group: efficiency, the risk of hypoglycemia, effects on body weight, the demonstrated effect in cardiovascular risk, nephroprotection, limitation of use in renal insufficiency, the rate of secondary effects, complexity and costs. Additionally, the document details combination options, and develop the start and adjustment of available injectable therapies.
2型糖尿病（DM2）因其在全球范围内的高患病率及其不断增长的趋势，以及与之相关的个人和经济成本，已成为一个全球性问题。正确的治疗可以降低死亡率和相关并发症。最近，一些新概念已被纳入常规临床实践，并改变了DM2药物治疗的算法。因此，西班牙糖尿病学会（SED）委托共识与临床指南工作组对2010年的文件《2型糖尿病高血糖药物治疗建议》进行更新。新的方面包括描述每个药物组的九个特征：疗效、低血糖风险、对体重的影响、对心血管风险的已证实作用、肾脏保护作用、在肾功能不全中的使用限制、副作用发生率、复杂性和成本。此外，该文件详细介绍了联合用药方案，并阐述了现有注射疗法的起始和调整方法。
